Article info

Download PDFPDF
Original research
Superior effects of natalizumab versus other DMTs on patient-reported outcomes in people with multiple sclerosis

Authors

  • Jing Chen Department of Geriatrics, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaKey Laboratory of Diagnosis and Treatment of Aging and Physic-chemical Injury Diseases of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China PubMed articlesGoogle scholar articles
  • Ibrahima Diouf Clinical Outcomes Research Unit (CORe), Faculty of Medicine, University of Melbourne, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Bruce V Taylor Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia PubMed articlesGoogle scholar articles
  • Tomas Kalincik Clinical Outcomes Research Unit (CORe), Faculty of Medicine, University of Melbourne, Melbourne, Victoria, AustraliaDepartment of Neurology, The Royal Melbourne Hospital City Campus, Parkville, Victoria, Australia PubMed articlesGoogle scholar articles
  • Ingrid van der Mei Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Ingrid van der Mei, Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS 7005, Australia; ingrid.vandermei{at}utas.edu.au
View Full Text

Citation

Chen J, Diouf I, Taylor BV, et al
Superior effects of natalizumab versus other DMTs on patient-reported outcomes in people with multiple sclerosis

Publication history

  • Received March 9, 2022
  • Accepted July 5, 2022
  • First published July 28, 2022.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.